Area of research
Genetics · Molecular Biology
Research interest
Research interests include Glioma Diagnosis and Treatment, Cancer, Hypoxia, and Metabolism, ATP Synthase and ATPases Research, and Lung Cancer Treatments and Mutations.
Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses
Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence
Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance
A Novel Blood-Brain Barrier-Permeable Chemotherapeutic Agent for the Treatment of Glioblastoma
Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)
Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma
Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations
The genetic landscape of anaplastic pleomorphic xanthoastrocytoma
Evaluation of Three Morphologically Distinct Virus-Like Particles as Nanocarriers for Convection-Enhanced Drug Delivery to Glioblastoma
Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience
Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma
Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors
Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy
Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors
Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model
Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis
Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children
Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment
Sensitivity of Glioblastomas to Clinically Available MEK Inhibitors Is Defined by Neurofibromin 1 Deficiency
Cooperative interactions of BRAF <sup>V600E</sup> kinase and <i>CDKN2A</i> locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy
Kinetics of Inhibitor Cycling Underlie Therapeutic Disparities between EGFR-Driven Lung and Brain Cancers